Compare ARQT & SHOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | SHOO |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | 2020 | 1996 |
| Metric | ARQT | SHOO |
|---|---|---|
| Price | $27.30 | $42.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $34.00 | ★ $42.14 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.27% |
| EPS Growth | ★ 88.79 | N/A |
| EPS | N/A | ★ 1.00 |
| Revenue | $376,072,000.00 | ★ $2,534,109,000.00 |
| Revenue This Year | $34.85 | $12.39 |
| Revenue Next Year | $29.39 | $5.90 |
| P/E Ratio | ★ N/A | $42.09 |
| Revenue Growth | ★ 91.34 | 11.00 |
| 52 Week Low | $13.70 | $22.26 |
| 52 Week High | $31.77 | $47.11 |
| Indicator | ARQT | SHOO |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 49.54 |
| Support Level | $24.96 | $36.08 |
| Resistance Level | $27.79 | $44.62 |
| Average True Range (ATR) | 1.25 | 1.43 |
| MACD | -0.19 | 0.07 |
| Stochastic Oscillator | 32.90 | 67.31 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.